
    
      This is a Phase III, multi-center,double-blind, randomised study assessing the efficacy and
      safety of SH-1028 tablets (200 mg orally, once daily) versus a standard of care (SoC)
      Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) ( gefitinib, 250 mg
      orally, once daily) in patients with locally advanced or metastatic Non-small Cell Lung
      Cancer (NSCLC) that is known to be EGFR sensitising mutation (EGFRm) positive,
      treatment-naive and eligible for first-line treatment with an EGFR-TKI.
    
  